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Clinics and pathology 
Disease 
Only one case available to date: a 54 yr old man with
chronic myelomonocytic leukaemia. 
Prognosis 
Yet unknown. 




Contains from N-term to C-term: a ligand binding 
domain, a transmembrane domain, and a Tyrosine 
kinase domain; PDGFRB is the receptor for PDGFB 
(platelet-derived growth factor-b); membrane protein; 




Contains a leucine zipper and, in C-term, a region with










5' HIP1- 3' PDGFRb; breakpoint in PDGFRb similar to 
what is found in the t(5;12)(q33;p12). 
Fusion protein 
Description 
180 kDa; contained nearly all of the HIP1 coding 
sequence, including the leucine zipper and talin 
homology domains, fused in frame to the 
transmembrane and tyrosine kinase domain of the 
PDGFb; the reciprocal PDGFb-HIP1 transcript is not 
expressed. 
Oncogenesis 
Constitutive activation of PDGFb (by tyrosine 
autophosphorylation). 
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